BioSpace News Archive

Drug Development

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis- Positive feedback from FDA to initiate Phase 3 trial of atacicept in patients with LN -

Vera Therapeutics, Inc. announced plans to initiate a Phase 3 clinical trial of its lead product candidate atacicept in lupus nephritis (LN).

January 18, 2022
·
5 min read
FDA

Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue

Antares Pharma, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue.

January 18, 2022
·
5 min read
Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders

Enveric Biosciences today released a letter to shareholders from Dr. Joseph Tucker , Chief Executive Officer of Enveric Biosciences.

January 18, 2022
·
6 min read
Pharm Country

SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, announced that it will be participating in Edison Group’s Open House Event, scheduled to take place virtually this month.

January 18, 2022
·
2 min read
Drug Development

Akeso’s AK117 (CD47 monoclonal antibody) in Combination with AK112 (PD-1/VEGF bi-specific antibody) to Initiate a Phase Ib/II Clinical Trial with or without Chemotherapy for the Treatment of Advanced Malignant Tumors

Akeso, Inc. has obtained approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the People’s Republic of China (''China’’) to initiate a phase Ib/II clinical trial with or without chemotherapy for the treatment of advanced malignant tumors.

January 18, 2022
·
4 min read
Business

Fountain Therapeutics Announces Appointment of Anupama Hoey as Chief Business Officer

Fountain Therapeutics today announced the appointment of Anupama Hoey as chief business officer (CBO) effective January 17 th , 2022.

January 18, 2022
·
3 min read
Drug Development

Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma

Evaxion Biotech A/S (NASDAQ: EVAX), announced today it has received clearance from the Australia Therapeutic Goods Administration to initiate a Phase 2b trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s (known as MSD outside the United States and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

January 18, 2022
·
5 min read
Pharm Country

PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference

PDS Biotechnology Corporation announced that its management will present at the B. Riley Securities Virtual Oncology Conference on January 28, 2022.

January 18, 2022
·
2 min read
Biotech Beach

Codex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics

Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that its R&D team has used the company’s proprietary short oligo ligation assembly (SOLA) enzymatic DNA synthesis (EDS) technology to successfully construct the hemagglutinin (H1) and neuraminidase (N1) genes from the influenza A virus genome.

January 18, 2022
·
5 min read
Biotech Bay

Gracell Biotechnologies to Participate in B Riley Securities 2022 Virtual Oncology Conference

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that the management team will participate in the B Riley Securities 2022 Virtual Oncology Conference from January 27th to 28th.

January 18, 2022
·
1 min read